Biogen (BIIB) Total Current Liabilities (2009 - 2026)

Biogen has reported Total Current Liabilities for 18 years, with the latest figure at $3.9 billion in Q2 2026.

• On a quarterly basis, Total Current Liabilities rose 23.04% year-over-year to $3.9 billion in Q2 2026; TTM through Jun 2026 was $3.9 billion, a 23.04% increase from a year earlier, with the FY2025 full-year figure at $3.3 billion, down 39.42% from the prior year.
• Total Current Liabilities was $3.9 billion for Q2 2026 at Biogen, up from $3.0 billion in the prior quarter.
• The five-year high for Total Current Liabilities was $5.5 billion in Q4 2024, with the low at $3.0 billion in Q1 2026.
• Average Total Current Liabilities over 5 years is $3.9 billion, with a median of $3.4 billion recorded in 2023.
• The sharpest annual moves came in 2025 and 2026: Total Current Liabilities surged 64.37% in 2025, then slumped 43.39% in 2026.
• Over 5 years, Total Current Liabilities stood at $3.3 billion in 2022, then rose by 4.93% to $3.4 billion in 2023, then surged by 60.99% to $5.5 billion in 2024, then sank by 39.42% to $3.3 billion in 2025, then advanced by 16.95% to $3.9 billion in 2026.
• The last three Total Current Liabilities figures came in at $3.9 billion (Q2 2026), $3.0 billion (Q1 2026), and $3.3 billion (Q4 2025), per Business Quant data.